Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab

被引：0

作者：

Rimini, M. ^{[1
]}

Amadeo, E. ^{[1
]}

Vitiello, F. ^{[2
]}

Foti, S. ^{[2
]}

Persano, M. ^{[3
]}

Tada, T. ^{[4
]}

Suda, G. ^{[5
]}

Shimose, S. ^{[6
]}

Kudo, M. ^{[7
]}

Cheon, J. ^{[8
]}

Finkelmeier, F. ^{[9
]}

Lim, H. Y. ^{[10
]}

Piscaglia, F. ^{[11
]}

Masi, G. ^{[12
]}

Yoo, C. ^{[13
]}

Lonardi, S. ^{[14
]}

Rossari, F. ^{[15
]}

Camera, S. ^{[16
]}

Gardini, A. Casadei ^{[17
]}

Presa, J. ^{[18
]}

机构：

[1] IRCCS Osped San Raffaele, Med Oncol, Milan, Italy

[2] IRCCS Osped San Raffaele, Oncol, Milan, Italy

[3] AOU Cagliari Osped Civile, Med Oncol Dept, Cagliari, Italy

[4] Japanese Red Cross Soc Himeji Hosp, Internal Med, Himeji, Hyogo, Japan

[5] Hokkaido Univ, Oncol, Sapporo, Hokkaido, Japan

[6] Kurume Univ Hosp, Med Oncol Dept, Kurume, Fukuoka, Japan

[7] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[8] Ulsan Univ Hosp, Div Hematol & Oncol, Ulsan, South Korea

[9] Johannes Wolfgang Goethe Univ, Univ Klinikum Frankfurt, Dept Med Oncol, Frankfurt, Germany

[10] Sungkyunkwan Univ, Samsung Med Ctr SMC, Sch Med, Oncol, Seoul, South Korea

[11] AOU Policlin S Orsola Malpighi, Oncol, Bologna, Italy

[12] Osped Santa Chiara, Med Oncol, Pisa, Italy

[13] Univ Ulsan, Coll Med, Asan Med Ctr, Oncol Dept, Seoul, South Korea

[14] IOV Ist Oncol Veneto IRCCS, Oncol Dept, Padua, Italy

[15] UniSR Univ Vita Salute San Raffaele Milano, Dept Med Oncol SR Tiget, Milan, Italy

[16] IRCCS Osped San Raffaele, Dipartimento Oncol Med, Milan, Italy

[17] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy

[18] Ras Os Montes Alto Douro Hosp Ctr, Oncol, Vila Real, Portugal

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.767

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

188P

引用

页码：S1548 / S1548

页数：1

共 50 条

[31] Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database
Kaplan, David E.
Tan, Ruoding
Xiang, Cheryl
Mu, Fan
Hernandez, Sairy
Ogale, Sarika
Li, Jiayang
Lin, Yilu
Shi, Lizheng
Singal, Amit G.
CANCERS, 2024, 16 (20)
[32] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
Su, Dan
Wu, Bin
Shi, Lizheng
JAMA NETWORK OPEN, 2021, 4 (02)
[33] Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
Persano, Mara
Rimini, Margherita
Gardini, Andrea Casadei
EUROPEAN JOURNAL OF CANCER, 2023, 192
[34] IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Mertens, Joachim
Kim, Tae-You
Kudo, Masatoshi
Lim, Ho Yeong
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Feng, Yin-Hsun
Verret, Wendy
Nicholas, Alan
Li, Lindong
Ma, Ning
Zhu, Andrew X.
Cheng, Ann-Lii
SWISS MEDICAL WEEKLY, 2021, 151 : 25 - 26
[35] IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Lim, Ho Yeong
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Feng, Yin-Hsun
Verret, Wendy
Nicholas, Alan
Li, Lindong
Ma, Ning
Zhu, Andrew X.
Cheng, Ann-Lii
CANCER RESEARCH, 2021, 81 (13)
[36] Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma
Nakabori, Tasuku
Higashi, Sena
Abe, Yutaro
Mukai, Kaori
Ikawa, Toshiki
Konishi, Koji
Maeda, Noboru
Nakanishi, Katsuyuki
Hasegawa, Shinichiro
Wada, Hiroshi
Ohkawa, Kazuyoshi
CURRENT ONCOLOGY, 2024, 31 (03) : 1543 - 1555
[37] Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis
Hou, Yanli
Wu, Bin
CANCER COMMUNICATIONS, 2020, 40 (12) : 743 - 745
[38] Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
Maesaka, Kazuki
Sakamori, Ryotaro
Yamada, Ryoko
Tahata, Yuki
Imai, Yasuharu
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Mita, Eiji
Ito, Toshifumi
Hagiwara, Hideki
Yakushijin, Takayuki
Kodama, Takahiro
Hikita, Hayato
Tatsumi, Tomohide
Takehara, Tetsuo
HEPATOLOGY RESEARCH, 2022, 52 (03) : 298 - 307
[39] Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis
Giri, Suprabhat
Angadi, Sumaswi
Vaidya, Arun
Singh, Ankita
Roy, Akash
Sundaram, Sridhar
CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 228 - 235
[40] Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
Mah I Kan Changez
Maimoona Khan
Muhammad Uzair
Muhammad Fawad Tahir
Maryam Mohsin
Amna Faiyaz Hussain
Vania Saqib
Muhammad Khizer Molani
Aisha Habib Ahmed
Saad Khalid
Journal of Gastrointestinal Cancer, 2024, 55 : 467 - 481

← 1 2 3 4 5 →